Improving breast cancer therapy by inhibiting CCL2 cell signalling
Finish Year: 2013
Chief Investigator: Dr Trina Stewart
Institution: University of Melbourne
Early Career Fellowship
This study investigates the potential of inhibiting a particular cell signalling protein, termed CCL2, for the treatment of breast cancer. The production of CCL2 by both cancer cells and also by some immune suppressing cells can enhance the aggressiveness of cancer progression and its resistance to existing therapies. A high level of serum CCL2 has been associated with a poor prognosis for breast cancer patients.
In preclinical models of breast cancer, it has been shown that inhibiting the actions of CCL2 can reduce primary tumour growth and also its spread (metastases). A better understanding of the role of CCL2 in cancer progression and how inhibiting CCL2 can be used to treat breast cancer will therefore allow us to design more effective therapeutic strategies for the treatment of patients with breast cancer.